---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-25-000007"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:44:04.275465+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics announces preliminary 2024 revenue of $814M, exceeding guidance, and 2025 financial outlook

## Summary
- Preliminary 2024 total revenue ~$814M, net product revenue ~$601M, and Evrysdi royalties ~$211M.
- Four FDA approval applications submitted in 2024, including sepiapterin for PKU with FDA action date July 29, 2025 and CHMP opinion expected Q2 2025.
- License and collaboration agreement with Novartis for PTC518 (Huntington's disease) closed, with $1B upfront and up to $1.9B milestones.
- 2025 revenue guidance $600M-$800M; GAAP R&D and SG&A expense $805M-$835M; non-GAAP $730M-$760M.
- PIVOT-HD Phase 2 data readout expected Q2 2025; cash balance ~$1.1B plus additional $1B from Novartis upfront.

## SEC filing metadata
- accession: 0001070081-25-000007
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008125000007/0001070081-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008125000007/tmb-20250113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-25-000007
- JSON: https://secwatch.observer/filing/0001070081-25-000007.json
- Plain text: https://secwatch.observer/filing/0001070081-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.